No new or unexpected safety signals emerged from the Phase 3 data that had not already been identified in Phase 2
WATCH OUR ABC GLOBAL ALLIANCE WEBINAR: "ADVOCACY TOOLS TO IMPROVE ACCESS TO MEDICINES" #EUWeekAgainstCancer #AccessToMedicines #BreastCancer #HealthEquity #TBCT #WomensHealth To view or add a comment, sign in Only half of cancer medicines approved by the European Medicines Agency in 20202023 are available in EU countries (on average) Average time from EMA approval to patient access: 586 days, with major variation between Member States Access to biomarker testing, essential for personalised cancer treatment, is inconsistent across Europe Reducing disparities in access to medicines and diagnostics is essential to ensure innovation benefits all patients, wherever they live
Beyond appetite suppression, GLP-1 medications improve blood sugar control and enhance insulin secretion in response to meals
The SASP represents a mechanism by which senescent cells may function in a non-autonomous fashion
SOD, an oxido-reductase, occurs in three forms, each defined by the metals present
Moderate to Severe Deficiency : This requires a "loading phase." Guidelines suggest 1,000 mcg several times a week (often alternate days) for the first one to two weeks
